ライフサイエンスコーパス: investigator

1 was performed by one histologically trained investigator.

2 ssed as not related to the study drug by the investigator.

3 t was listed as possibly contributing by the investigator.

4 analysed data were shared with the principal investigator.

5 ts and treatments were performed by the same investigator.

6 ants in DoS were awarded to more experienced investigators.

7 related to ofatumumab treatment by the study investigators.

8 hilanthropic support on early career surgeon-investigators.

9 e more than 60 years of concerted efforts by investigators.

10 en studied separately by different fields of investigators.

11 onal resource in collaboration with Sentinel investigators.

12 atures associated with MVI reported by other investigators.

13 symptoms and objective criteria reported by investigators.

14 roducibility of outcomes for talented junior investigators.

15 as inspiration for all surgeons and surgical investigators.

16 l appraisal was completed independently by 2 investigators.

17 et, such a feature would be highly useful to investigators.

18 d ratio for the primary composite end point: investigators, 0.83 (95% CI, 0.76-0.91) versus CEC, 0.82

19 e objective response rate as assessed by the investigator according to both Response Evaluation Crite

20 lete or partial response) as assessed by the investigators according to RECIST 1.1.

21 Investigators acknowledge the limitations of rodent or n

22 cent years motivates the talents of numerous investigators across the world.

23 Prespecified end points, reported by investigators (all cardiologists) using specific case re

24 Data were abstracted by 1 investigator and confirmed by a second.

25 (partial response or better) assessed by the investigator and confirmed by independent review.

26 Data were abstracted by 1 investigator and verified by a second.

27 udication of prespecified end points made by investigators and by the CEC.

28 erwise uninvolved research associate so that investigators and clinicians were fully masked to alloca

29 Investigators and clusters were blinded to randomisation

30 Patients, investigators and individuals involved in the analysis o

31 The 2 models are usually unknown to the investigators and must be estimated.

32 In this follow-up study, investigators and participants remained unaware of the t

33 Investigators and participants were aware of treatment a

34 Investigators and participants were unmasked to treatmen

35 were masked to the treatment assignment, but investigators and patients were aware of treatment alloc

36 Investigators and patients were aware of treatment alloc

37 Investigators and patients were not masked to treatment.

38 ased molecular approach will be valuable for investigators and promote therapeutic decision-making an

39 blinded, independent radiology review and by investigators) and locally assessed prostate-specific an

40 recurrence-free survival, as assessed by the investigator, and was analysed in the intention-to-treat

41 Participants, investigators, and assessors were masked to treatment as

42 Patients, investigators, and clinical staff were masked to patient

43 AMD, avoid discrepancies between clinicians/investigators, and establish structure/function correlat

44 Participants, study investigators, and field workers were masked to treatmen

45 Patients, investigators, and MRI readers were unaware of treatment

46 Patients, investigators, and other study personnel were unaware of

47 t clinical trials, train a new generation of investigators, and perform innovative pilot studies.

48 Patients, investigators, and site staff were masked to the treatme

49 Patients, investigators, and study personnel were masked to treatm

50 Patients, investigators, and study team members were masked to tre

51 Patients, investigators, and the funder of the study were masked t

52 Patients, investigators, and the study sponsor (except members of

53 Participants, investigators, and trial sponsor were masked to group as

54 Investigators are addressing the current obstacles with

55 Investigators are employing unprecedented innovation in

56 Clinical investigators are encouraged to consider applying these

57 At present, investigators are primarily focused on improving DBS dev

58 Disparities exist among grantees, and female investigators are underrepresented, especially among pra

59 Data come from investigators around the world and represent a broad sco

60 ic adenocarcinoma, which was assessed by the investigator as related to ruxolitinib treatment.

61 n the liraglutide group, was assessed by the investigator as unlikely to be related to the trial trea

62 le investigator was confirmed by a second, 2 investigators assessed risk of bias, and evidence certai

63 l eradication) at day 14 (primary endpoint), investigator-assessed clinical response at day 14, and 3

64 edicines Agency-defined primary endpoint was investigator-assessed clinical success at the test-of-cu

65 Investigator-assessed clinical success at the TOC visit

66 SIs, in terms of early clinical response and investigator-assessed clinical success at the TOC visit.

67 treated with single-agent EV 1.25 mg/kg, the investigator-assessed confirmed objective response rate

68 The primary endpoint was investigator-assessed objective response rate by RECIST

69 The primary endpoint was investigator-assessed objective response rate measured a

70 The primary endpoint was investigator-assessed overall response (at least a minor

71 The primary endpoint was investigator-assessed progression-free survival accordin

72 In our sensitivity analysis of investigator-assessed progression-free survival at the o

73 The primary endpoint was investigator-assessed progression-free survival in the i

74 The primary endpoint was investigator-assessed progression-free survival per Resp

75 Coprimary endpoints were investigator-assessed progression-free survival per Resp

76 The primary endpoint was investigator-assessed progression-free survival, and ana

77 All studies had a primary endpoint of investigator-assessed progression-free survival, defined

78 The primary outcome was investigator-assessed progression-free survival.

79 s for the intention-to-treat population were investigator-assessed Response Evaluation Criteria in So

80 The key secondary endpoint was investigator-assessed response rate in the dose-expansio

81 Here, we report prespecified, investigator-assessed, exploratory post-progression endp

82 ents with an objective response according to investigator assessment was 121 (79%, 95% CI 72-85) of 1

83 Overall response by investigator assessment was seen in 37 patients (35.2%;

84 ed ORRs per independent radiology review and investigator assessment were 43.5% (95% CI, 31.0% to 56.

85 ponse rate and progression-free survival per investigator assessment were recorded.

86 ary endpoint was recurrence-free survival by investigator assessment, and overall survival was a key

87 o 10.7 months (second line), on the basis of investigator assessment, were observed.

88 RECIST 1.1 criteria to CNS target lesions by investigator assessment.

89 as permitted on radiological progression per investigator assessment.

90 Iannis Aifantis is a principal investigator at NYU Langone Medical Center, and his labo

91 ar and Developmental Biology at Yale, and an Investigator at the Howard Hughes Medical Institute.

92 Although patients and investigators at a given centre were not masked to treat

93 On eligibility confirmation, investigators at each site telephoned an interactive voi

94 Despite strikingly similar efficacy, investigators at multiple centers participating in these

95 tre were not masked to treatment assignment, investigators at other centres and those in the clinical

96 ients responded poorly to doxycycline, which investigators attributed to doxycycline resistance.

97 eons has administered the Jacobson Promising Investigator Award (JPIA), which recognizes surgeon-scie

98 American Society of Clinical Oncology Young Investigator Award, MSK's Ludwig Center, Weiss Family Ki

99 s Diseases; Rheumatology Research Foundation Investigator Awards and Medical Education Award; Boston

100 of variable duration, during which they and investigators became aware of treatment allocation.

101 ining that is prone to misinterpretation and investigator bias.

102 tidisciplinary (basic/translational/clinical investigators, bioinformaticians, geneticists, and physi

103 This multicenter, investigator-blind, phase 3, parallel-group trial assess

104 stitute by an experienced team of extramural investigators but never funded.

105 Participants and investigators, but not staff administering the vaccine,

106 Through this interface, investigators can easily observe copy number changes, mu

107 Investigators, clinicians, and patients were masked to t

108 Previous investigators concluded that the film weight is responsi

109 e primary efficacy end point was the rate of investigator-confirmed HAE attacks during the 24-week tr

110 ue to C1 inhibitor deficiency and at least 2 investigator-confirmed HAE attacks in the first 56 days

111 nsitive chemical protecting groups that give investigators control over activation of biomolecules us

112 of loss to follow-up, withdrawal of consent, investigator decision, and an unrelated death from a mot

113 atterns determined by empirical analyses and investigator-defined dietary indexes based on a predeter

114 y, fluorescein angiography, and OCT) for all investigator-determined cases of IOI, retinal arterial o

115 New-onset investigator-determined exudative AMD was reported more

116 from baseline and fewer FAi-treated eyes had investigator-determined macular edema at month 36 compar

117 The investigators developed a surgical mouse model in which

118 aliquots were prepared and are available to investigators developing laboratory diagnostics for Lyme

119 Investigators did an open-label, randomised controlled t

120 d febrile neutropenia in a prior cycle or at investigator discretion if patients had infections or tr

121 b Q2W, or both, was allowed after week 16 at investigator discretion.

122 l was given for six cycles, or longer at the investigators' discretion.

123 TAX Extended Survival (SYNTAXES) study is an investigator-driven extension follow-up of a multicentre

124 An investigator-driven, real-life follow-up study of adult-

125 arch community as they apply to early career investigators (ECIs).

126 Participating investigators enter de-identified data into an online pl

127 In this article, the investigators examine critical illness factors associate

128 rel use was allowed at the discretion of the investigator for up to 6 months after the qualifying rev

129 We provide a conceptual framework for investigators from diverse disciplines and indicate that

130 ic Research Consortium, composed of academic investigators from the United States and Europe, patient

131 be improved across the entire spectrum from investigators, funding agencies, as well as during the p

132 e proportion of patients who had achieved an Investigator Global Assessment response (score of 0 [cle

133 e proportion of patients who had achieved an Investigator Global Assessment response was significantl

134 ) with moderate-to-severe atopic dermatitis (Investigator Global Assessment score >=3, Eczema Area an

135 The AREDS2-10Y investigators graded each SD-OCT scan for the presence/a

136 For detecting retinal fluid, the investigators had an accuracy of 0.805 (95% confidence i

137 of in vitro mechanistic studies by multiple investigators has led to the conclusion that addition of

138 Most investigators have focused on investigating the function

139 Investigators have hypothesized that chronic systemic lo

140 Even though other investigators have reported epitope mapping in the H5 HA

141 Other investigators have since demonstrated the ability of Sof

142 d gene family in cancers, and, consequently, investigators have sought an effective RAS inhibitor for

143 ge gaps and future directions for providers, investigators, health systems, and policymakers.

144 ical analysis) and reporting but do not tell investigators how to design and perform their experiment

145 Investigators identified 7529 prespecified end points, 6

146 Using the computable phenotype, investigators identified over 650 000 potentially eligib

147 In 12 canines, the investigators implanted epicardial pacemakers and radiot

148 of patients) and safety were assessed by the investigator in all patients who received at least one d

149 atients with and without LD are available to investigators in academia and industry for evaluation or

150 edical PhD graduates do not become Principal Investigators in academic laboratories.

151 of results were performed by two independent investigators in accordance with the PRISMA statement.

152 was objective response as assessed by local investigators in an intention-to-treat analysis.

153 At this point, most investigators in diabetes are aware of the success of mi

154 Investigators in previous studies have drawn inconsisten

155 utions for funding and retaining early-stage investigators in research that supports the National Ins

156 s of Health (NIH) grants awarded to surgical investigators, including potential disparities.

157 Two investigators independently assessed study quality.

158 Two investigators independently rated study quality.

159 Two investigators independently screened titles, abstracts,

160 The RECIPE trial was an investigator initiated single-center, single-blind prosp

161 In a single-arm, first-in-human, investigator-initiated Food and Drug Administration Inve

162 rtWare Left Ventricular Assist System was an investigator-initiated multicenter, prospective, single-

163 evention enrolled as part of the prospective investigator-initiated study (IIS) SEDMAN Study.

164 imary objective in this phase 1 multicenter, investigator-initiated study was to determine maximum to

165 This investigator-initiated, double-blinded, placebo-controll

166 The authors conducted an investigator-initiated, multicenter, double-blind, rando

167 for Primary Percutaneous Intervention) is an investigator-initiated, multicenter, open-label, randomi

168 in Elderly with Myocardial Infarction) is an investigator-initiated, multicenter, randomized clinical

169 ial Fibrillation (ERADICATE-AF) trial was an investigator-initiated, multicenter, single-blind, rando

170 Untreated Persistent AF (VENUS) trial was an investigator-initiated, National Institutes of Health-fu

171 This study was an investigator-initiated, open-label, non-randomised, sing

172 This was a multinational, randomized, investigator-initiated, open-label, noninferiority trial

173 In this international, investigator-initiated, parallel-group, open, blinded-ou

174 Olaparib Expanded, an investigator-initiated, phase II study, assessed olapari

175 In this open-label, investigator-initiated, randomised phase 2 trial followi

176 In this investigator-initiated, randomized, double-blind, placeb

177 This investigator-initiated, randomized, open-label trial eva

178 his in mind, a multicountry collaboration of investigators interested in LMIC STEMI care have tried t

179 d in an established CBT clinic and the chief investigator is the originator of MCT and group differen

180 An interest of many investigators is identifying traits or diseases that sha

181 nt change of the final result as compared to investigator judgment.

182 The ONE Study consisted of seven investigator-led, single-arm trials done internationally

183 Two investigators manually defined regions of interest in th

184 Meanwhile, an impatient community of investigators met together in the Makarska Conference, o

185 For detecting subretinal fluid, the investigator metrics were 0.946 (95% CI, 0.931-0.958), 0

186 In these analyses, investigators must assume that the instrument is as-if r

187 Clinical investigators need to embrace a COVID-19 new normal and

188 m the Pediatric Acute Lung Injury and Sepsis Investigators Network, the EBMT, the Pediatric Blood and

189 d samples, which is particularly relevant to investigators of large-scale population health and epide

190 CA1/2 mutation carriers in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA; N = 31 448

191 We invited investigators of published cohorts of patients undergoin

192 Investigators of the eligible studies published from 199

193 report to the National Heart Institute from investigators of the National Diet-Heart Feasibility Stu

194 In the pursuit of this aim, investigators often perform analyses that make certain a

195 Allocation was not masked to investigators or patients.

196 The sponsor, investigators, other study site staff (except for the un

197 In addition, the sponsor, the investigators, other study site staff, and patients were

198 ve tumor measurements performed by the local investigator, overall survival (OS), time to worsening o

199 50 years ago, the neural crest has intrigued investigators owing to its remarkable developmental pote

200 Investigator pairs assessed risk of bias by using valida

201 Investigators, participants and their parents or guardia

202 The trial sponsor, investigators, participants, and the study staff who pro

203 Principal investigators, patient advocacy groups, research assista

204 Investigators, patients, and the funder were masked to t

205 Tumor assessments were evaluated by investigators per immune-related RECIST.

206 criteria were selected, and two independent investigators performed data extraction; overall surviva

207 article, we present advice to both principal investigators (PIs) and postdocs for successfully naviga

208 Principal investigators' (PIs) data were extracted from publicly a

209 Investigators posed as either a Medicaid or a privately-

210 Consortium for Food Allergy Research investigators previously reported 52-week outcomes from

211 CONSORT-AI recommends that investigators provide clear descriptions of the AI inter

212 SPIRIT-AI recommends that investigators provide clear descriptions of the AI inter

213 The most common investigator-provided reasons for failure among early en

214 eported by the patient will be missed by the investigators, reducing the power of the study and misre

215 opposed to the oft-repeated suggestion that investigators rely upon a few agreed upon packages.

216 ), supported by Novartis Pharma AG, analyzed investigator-reported cases of intraocular inflammation

217 revised as a result of external results, was investigator-reported disease-free survival (DFS) compar

218 The SRC reviewed data from cases of investigator-reported IOI (60/1088 brolucizumab-treated

219 Patients, investigators, research staff, and the sponsor study tea

220 ll types has largely been left to individual investigators, resulting in widely varying nomenclature

221 nknown compounds from the raw data to reduce investigator's bias and to vastly accelerate overall ana

222 0-100 mg/m(2) on days 1-3 of each cycle with investigator's choice of either carboplatin area under t

223 ral ruxolitinib (10 mg twice daily) with the investigator's choice of therapy from a list of nine com

224 (5 mg/mL per min) or cisplatin (75 mg/m(2); investigator's choice) every 3 weeks for four cycles, fo

225 ease progression, unacceptable toxicity, the investigator's decision to discontinue, or participant w

226 d optional prophylactic cranial irradiation (investigator's discretion).

227 one optional dose at week 46 that was at the investigator's discretion, and intravenous pembrolizumab

228 The primary efficacy outcome was the investigator's global assessment (IGA) of a status of cl

229 tus (PP) numeric rating scale (NRS), and the Investigator's Global Assessment (IGA) were assessed.

230 verity Index (71.6% vs 15.5%; P < .0001) and Investigator's Global Assessment responses (38.0% vs 7.7

231 NCT03011892), 307 adult patients with AD, an Investigator's Global Assessment score of 2 or 3 (mild o

232 r venous thromboembolism on the basis of the investigator's judgment to receive either rivaroxaban or

233 erature is common but greatly depends on the investigator's prior knowledge of specific compound clas

234 nd psychiatry hold lessons for each other as investigators search for actionable, biological underpin

235 otein HOS elucidation and as a reference for investigators seeking a MS-based tool to address structu

236 ts layers, and this presents a challenge for investigators seeking to decipher hippocampal structure

237 cs tools to analyze FT-MS data that will aid investigators seeking to understand the availability of

238 The investigator selected one of the two protocol-approved s

239 estionnaire EORTC QLQ-C30 plus QLQ-LC29, and investigators selected half of these patients to complet

240 vir and 800 mg darunavir per day), both with investigator-selected nucleoside reverse transcriptase i

241 In future research, investigators should evaluate other demographic groups.

242 with commercially distributed food vehicles, investigators should thoroughly investigate all noroviru

243 seline rate of surgical site infections, the investigators sought to determine the frequency of infec

244 multicenter, open-label, randomized phase II investigator-sponsored neoadjuvant trial with funding pr

245 ional efforts by all stakeholders, including investigators, sponsors, regulators, societies, editors,

246 resenting a diverse array of subject matter, investigators, study design, institutions, and countries

247 Sponsors, investigators, study site personnel, and patients were m

248 All patients, investigators, study staff, and pharmacists were masked

249 Other investigators studying facilitation have focused on Ca(r

250 Investigators supplied results for event-free survival,

251 Rs) reported during postinjection visits and investigator telephone calls were collected.

252 sponsor's medical director together with the investigators that patients with PDGFRA D842V mutations

253 Among NIH-funded investigators, the median grant funding was $1.6M (IQR $

254 had fatal pneumonia that was assessed by the investigator to be treatment related.

255 reat interest for a biomedical analyst or an investigator to correctly model the CD4 cell count or di

256 e spatial resolution of some cameras allowed investigators to confirm 22 flashes with HWHM greater th

257 tes of Health implemented a policy requiring investigators to consider sex as a biological variable.

258 s, this article provides recommendations for investigators to consider when planning and executing hu

259 We invite all investigators to contribute additional data and annotati

260 ad of genetic engineering technology enabled investigators to develop models of familial AD by overex

261 ems and common assays that have been used by investigators to dissect these features and that will ho

262 uilt an open-access web application allowing investigators to estimate the degree of variance expecte

263 Our findings can help investigators to focus on key aspects most in need of at

264 Adjusting size and zeta potential may allow investigators to further fine-tune delivery to lymphoid

265 s and their canonical counterparts, allowing investigators to identify energetic differences and prov

266 ica-specific genotyping array, which enables investigators to identify novel disease associations and

267 RIME allows investigators to leverage external validation data to ac

268 These tests require investigators to make covariate-by-covariate judgments a

269 Laboratory data allowed investigators to rapidly link infections to contaminated

270 articipant flow diagrams and contacted study investigators to request data.

271 ith a focus on the transition of early stage investigators to research independence, we outline chall

272 These findings led several investigators to test the hypotheses that treatment of a

273 We masked participants and investigators to treatment allocation throughout the stu

274 protocol is intended not only as a guide for investigators trying to establish an FPOP platform in th

275 del receded over the past several decades as investigators turned to genetically tractable systems.

276 TarPan Viewer helps investigators understand data from targeted sequencing d

277 ssessment were not gathered by the principal investigator until all other study procedures were compl

278 al register were searched by two independent investigators up to March 2019.

279 To achieve these goals, investigators used the statin and dosage of their choice

280 Data extraction by a single investigator was confirmed by a second, 2 investigators

281 ssion-free survival as assessed by the study investigator was significantly prolonged with atezolizum

282 The purpose of this meeting of NCI-sponsored investigators was to identify local institutional standa

283 Wan Kim's initial efforts as an independent investigator were focused on improving the understanding

284 All laboratory investigators were blind to treatment and participant al

285 Neither participants nor investigators were masked to dose allocation.

286 nt was ensured and patients, field team, and investigators were masked to group assignment.

287 Investigators were masked to the type of medication.

288 Participants and investigators were masked to treatment allocation until

289 Neither participants nor investigators were masked to treatment allocation.

290 Participants and investigators were masked to treatment assignment until

291 ollowing central randomisation, patients and investigators were not masked to treatment assignment.

292 orded as adverse events at the discretion of investigators were reported in 13 participants (23%) in

293 ies to advance the academic careers of young investigators while they strived to make contributions t

294 Patients, physicians, and the investigators who analysed data were masked to treatment

295 and also endeavors to spark the curiosity of investigators who might enter this fascinatingly complex

296 The investigators who performed the index test were masked t

297 The trial was open label, and neither the investigators who took measurements of the lesions nor t

298 ceived >=1 dose), were centrally assessed by investigators who were unaware of treatment assignment.

299 tives can generate conflicts of interest for investigators, who may be inclined to withhold unfavorab

300 as well as the recent discoveries by leading investigators with an emphasis on significant open quest